Product Information
GABAPENTIN 400 MG CAPSULE is a generic product labeled by Actavis Pharma, Inc., priced at $0.0422 per EA under NDC 45963055750. Its NADAC has been published 647 times since May 14, 2014.
FDA first approved this application on Sep 12, 2003. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
400 mg/1
Manufacturer
Actavis Pharma, Inc.NDC
45963055750
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GABAPENTINApproval Type
Generic (ANDA)
FDA Application
ANDA075350FDA Approved
9/12/2003
TE Code
AB
On Market Since
4/3/2014
Pharmacological Classes
Price Statistics
The NADAC for GABAPENTIN 400 MG CAPSULE has been published 647 times since May 14, 2014, and over the history we have for it it has declined 53.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0422 per EA |
|---|---|
| All-time high | $0.0916 (Aug 13, 2014) |
| All-time low | $0.0396 (Apr 22, 2026) |
| 52-week high | $0.0434 |
| 52-week low | $0.0396 |
| Median price | $0.0646 |
| Average price | $0.0632 |
| Largest weekly change | +23.4% (Aug 21, 2024) |
| Weeks tracked | 647 |
| Tracking since | May 14, 2014 |
Generic Alternatives
The matcher finds 15 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 3% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Gabapentin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GABAPENTIN 400 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for GABAPENTIN 400 MG CAPSULE, manufactured by Actavis Pharma, Inc., is $0.0422 per EA (NDC 45963055750), effective Sep 30, 2026.
How has the price of GABAPENTIN 400 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for GABAPENTIN 400 MG CAPSULE has declined 53.0%. It has been tracked across 647 weekly CMS publications since May 14, 2014.
What are the highest and lowest recorded NADAC prices for GABAPENTIN 400 MG CAPSULE?
Since May 14, 2014, the NADAC for GABAPENTIN 400 MG CAPSULE has ranged from a low of $0.0396 (Apr 22, 2026) to a high of $0.0916 (Aug 13, 2014), with a median of $0.0646 per EA.
Are there cheaper alternatives to GABAPENTIN 400 MG CAPSULE?
Yes. 15 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, GABAPENTIN 400 MG CAPSULE, is $0.0410 per EA — about 3% below GABAPENTIN 400 MG CAPSULE.
Who manufactures GABAPENTIN 400 MG CAPSULE?
GABAPENTIN 400 MG CAPSULE (NDC 45963055750) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.